A novel therapeutic targeting of CD133 transcription in malignant neuroblastoma

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461614
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Research Institute for Clinical Oncology, Saitama Cancer Center (2014-2015); Chiba Cancer Center (Research Institute) (2013)
• Principal Investigator: Takenobu Hisanori 埼玉県立がんセンター(臨床腫瘍研究所), その他部局等, 研究員 (60392247)
• Co-Investigator(Kenkyū-buntansha): KAMIJO TAKEHIKO 埼玉県立がんセンター, 臨床腫瘍研究所, 所長 (90262708)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 幹細胞 / 発がん / 細胞分化

Outline of Final Research Achievements

We reported that CD133 suppressed differentiation in NB cells and CD133 was up-regulated in NB sphere (ONCOGENE, 2011). Further, CDX1 was identified as a transcription factor that directly induced CD133 expression in NB spheres by analysis of CD133 promoter region. CDX1 directly bound to CD133 promoter regions and up-regulated CD133 transcription, cell proliferation and NB sphere forming efficiency. Then, we developed tissue specific-overexpressing CD133 and CDX1 transgenic (Tg) mice. These Tg vectors were used to insert into the ROSA26 locus of mouse ES cells.

Free Research Field

医歯薬学